His primary areas of investigation include Internal medicine, Immunology, Gastroenterology, Hepatitis C and Liver disease. His work carried out in the field of Internal medicine brings together such families of science as Didanosine, Ribavirin and Surgery. His study in Hepatitis C virus, Viral disease, Virus and Hepacivirus falls under the purview of Immunology.
In Gastroenterology, Javier García-Samaniego works on issues like Viral load, which are connected to Interferon. His Hepatitis C study combines topics in areas such as Epidemiology and Disease burden. His study focuses on the intersection of Liver disease and fields such as Liver biopsy with connections in the field of Odds ratio, Alanine transaminase, Fibrosis, Hepatic fibrosis and Nodular regenerative hyperplasia.
His primary scientific interests are in Internal medicine, Virology, Hepatitis C virus, Gastroenterology and Immunology. Javier García-Samaniego combines subjects such as Chronic hepatitis and Ribavirin with his study of Internal medicine. The Virology study combines topics in areas such as Hiv infected patients and Genotype.
Javier García-Samaniego has included themes like Biopsy, Liver biopsy, Surgery, Viral load and Fibrosis in his Gastroenterology study. As part of his studies on Immunology, Javier García-Samaniego often connects relevant areas like Acquired immunodeficiency syndrome. His Hepatitis C study combines topics from a wide range of disciplines, such as Viral hepatitis and Epidemiology.
His primary areas of study are Internal medicine, Virology, Gastroenterology, Hepatitis C and Ribavirin. His biological study spans a wide range of topics, including Hepatitis C virus and Sofosbuvir. His studies in Virology integrate themes in fields like Allele, Immunology and Genotype.
His Gastroenterology research integrates issues from Hepatocellular carcinoma, Steatohepatitis, Fatty liver and Liver biopsy. The various areas that Javier García-Samaniego examines in his Hepatitis C study include Epidemiology, Virological response, Health policy, Voxilaprevir and Hcv genotype 1. His Epidemiology research focuses on Disease burden and how it connects with Viral load.
His scientific interests lie mostly in Internal medicine, Gastroenterology, Ribavirin, Hepatitis C virus and Hepatitis C. The study incorporates disciplines such as Paritaprevir and Ombitasvir in addition to Internal medicine. His Gastroenterology study incorporates themes from Hepatitis B, Liver biopsy, Diagnostic odds ratio, Likelihood ratios in diagnostic testing and Entecavir.
In his research on the topic of Ribavirin, Discontinuation, Confidence interval, Population study and Interquartile range is strongly related with Adverse effect. His Hepatitis C virus study results in a more complete grasp of Virology. The concepts of his Hepatitis C study are interwoven with issues in Voxilaprevir and Epidemiology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach;Stefan Zeuzem;Michael Manns;Ibrahim Altraif.
The Lancet Gastroenterology & Hepatology (2017)
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
Devin Razavi-Shearer;Ivane Gamkrelidze;Mindie H Nguyen;Ding-Shinn Chen.
The Lancet Gastroenterology & Hepatology (2018)
Historical epidemiology of hepatitis C virus (HCV) in selected countries
P. Bruggmann;T. Berg;A. L. H. Øvrehus;C. Moreno.
Journal of Viral Hepatitis (2014)
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C
Javier Garcı́a-Samaniego;Manuel Rodrı́guez;Juan Berenguer;Rafael Rodrı́guez-Rosado.
The American Journal of Gastroenterology (2001)
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study.
Luz Martín-Carbonero;Yves Benhamou;Massimo Puoti;Juan Berenguer.
Clinical Infectious Diseases (2004)
Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients.
Luz Martín-Carbonero;Vincent Soriano;Eulalia Valencia;Javier García-Samaniego.
AIDS Research and Human Retroviruses (2001)
Pegylated Ifn-α2b plus ribavirin as therapy for chronic hepatitis C in Hiv-infected patients
Mayte Pérez-Olmeda;Marina Núñez;Miriam Romero;Juan González.
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.
Marina Núñez;Celia Miralles;Miguel Angel Berdún;Elena Losada.
AIDS Research and Human Retroviruses (2007)
Strategies to manage hepatitis C virus (HCV) disease burden
H Wedemeyer;A S Duberg;M Buti;W M Rosenberg.
Journal of Viral Hepatitis (2014)
Hepatotoxicity after introduction of highly active antiretroviral therapy.
R Rodríguez-Rosado;J García-Samaniego;V Soriano.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: